published Apr 24, 2018, 3:16:53 PM, by David McLaughlin and Drew Armstrong (Bloomberg) — U.S. prosecutors are nearing their first charges against companies in an almost four-year-old criminal investigation into alleged price-fixing by generic-drug makers, according to people familiar with the matter. At least two companies are on track to